Asthma Trial Design To Be Focus Of Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK's investigational LABA could be the most impacted product as FDA's Pulmonary-Allergy Drugs Advisory Committee considers how to evaluate outcomes in the class.